This study tests a combination of drugs (defactinib, avutometinib, and nivolumab) for treating certain lung cancers that haven't responded to previous treatments. Lung cancer that has spread, and has a specific genetic change called LKB1 mutation, may be targeted by these drugs.

Key Points:

• **Study Length:** Cycles of treatment are repeated every 28 days and patients are followed up for 5 years.
• **Visits Required:** Patients will need to take medication and have regular tests like biopsies, blood samples, and scans.
• **Risks/Side Effects:** Possible side effects from the drugs, known and unknown, will be monitored.

Defactinib and avutometinib are kinase inhibitors that block proteins helping cancer cells grow. Nivolumab is an immunotherapy helping the body fight cancer cells. Together, they aim to slow or stop cancer growth. Eligibility includes being 18 or older, having certain types of lung cancer, and meeting health requirements. Exclusion criteria involve recent treatments, certain health conditions, or other medications. Participants must agree to use contraception and follow study guidelines.